A top Democratic senator is raising new concerns about Health and Human Services Secretary Tom Price’s trading of medical stocks and the firing of a U.S. attorney last week.
Sen. Ron WydenRon WydenThe Hill’s Whip List: Where Dems stand on Trump’s Supreme Court nominee Overnight Regulation: Senate moves to strike Obama-era internet privacy rules Overnight Tech: Senate votes to eliminate Obama internet privacy rules | FCC chief wants to stay out of 'political debate' on fake news | Wikileaks reveals new CIA docs MORE (Ore.), the top Democrat on the Senate Finance Committee, pointed to a report in ProPublica on Friday that U.S. Attorney Preet Bharara was investigating stock trades Price made while he was a congressman.
The Trump administration last week asked a range of U.S. attorneys to resign, including Bharara, then fired him when he refused to resign.
“I’m concerned that by firing U.S. Attorney Preet Bharara, the Trump Administration may be shutting down an investigation into Secretary Tom Price’s stock trading,” Wyden said in a statement.
Revelations that Price traded a range of medical stocks while a member of Congress involved in healthcare legislation were a central focus of Price’s confirmation hearings.
In particular, Democratic lawmakers pointed to Price’s purchase of discounted stock as part of a private offering for the biotech company Innate Immunotherapeutics.
Price defended his stock trades in the hearings and denied wrongdoing.
Democrats said he could have broken insider trading laws or a law against trading on congressional knowledge.
“Republicans rushed Secretary Price’s nomination through the Senate without getting answers to serious questions about his stock trades involving a tiny biotech startup with powerful Washington connections and other health care companies,” Wyden said.
“The American public deserves a full investigation of whether Tom Price used his public position for personal profit.”
Tags Ron Wyden